Dudediligence.

Beam Therapeutics Inc

BEAMNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$12.2M

15 notices · 442,585 sh

Oct 2025 to Oct 2026

Reported ·

$6,328,600

21 sales · 0 buys

Oct 2025 to Jun 2026

The two figures cover different periods.

20 of 21 reported sales carry the 10b5-1 box. Together they are 0.22% of the shares on issue.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Jun 2026N2025DJ2026FMAMJJASO2026-07-27: AMY SIMON, Form 1442026-06-30: JOHN M EVANS, Form 1442026-06-29: JOHN M EVANS, Form 1442026-04-14: CAROLE HO, Form 1442026-03-31: JOHN M EVANS, Form 1442026-04-02: CHRISTINE BELLON, Form 1442026-04-02: GIUSEPPE CIARAMELLA, Form 1442026-04-02: AMY SIMON, Form 1442026-04-02: JOHN M. EVANS, Form 1442026-03-30: JOHN M EVANS, Form 1442026-02-24: GIUSEPPE CIARAMELLA, Form 1442026-01-30: JOHN M EVANS, Form 1442026-01-29: JOHN M EVANS, Form 1442026-01-22: CHRISTINE BELLON, Form 1442026-01-15: CHRISTINE BELLON, Form 1442025-10-27: FMR LLC, sold2025-12-31: Bellon Christine, sold2025-12-31: Emany Sravan Kumar, sold2026-01-15: Bellon Christine, sold2026-01-20: Cavanagh Bethany J, sold2026-01-22: Bellon Christine, sold2026-01-22: Cavanagh Bethany J, sold2026-01-29: Evans John M., sold2026-02-24: Ciaramella Giuseppe, sold2026-03-30: Evans John M., sold2026-04-01: Ciaramella Giuseppe, sold2026-04-01: Bellon Christine, sold2026-04-01: Cavanagh Bethany J, sold2026-04-01: Simon Amy, sold2026-04-01: Evans John M., sold
under a no plan named▼ salesize is dollars

Form 144 notices, newest first

2026-07-27AMY SIMON, Chief Medical Officer$429,294
16,677 shplan 2026-03-27Form 4s on file end Jun 23144 ↗
2026-06-30JOHN M EVANS, CEO$857,685
25,000 shplan 2025-05-16Form 4s on file end Jun 23144 ↗
2026-06-29JOHN M EVANS, CEO$887,353
25,000 shplan 2025-05-16Form 4s on file end Jun 23144 ↗
2026-04-14CAROLE HO, Director$2,698,015
87,784 shno plan dateForm 4s on file end Jun 23144 ↗
2026-04-02CHRISTINE BELLON, Chief Legal Officer$438,000
20,000 shplan 2023-05-19144 ↗
Form 4, 2026-04-06: sold 5,956 at $24.58These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting... Form 4 ↗
2026-04-02GIUSEPPE CIARAMELLA, President$574,875
26,250 shplan 2023-05-23144 ↗
Form 4, 2026-04-06: sold 11,810 at $24.58These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting... Form 4 ↗
2026-04-02AMY SIMON, Chief Medical Officer$438,000
20,000 shplan 2023-05-19144 ↗
Form 4, 2026-04-06: sold 6,700 at $24.58These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting... Form 4 ↗
2026-04-02JOHN M. EVANS, CEO$1,464,541
66,874 shplan 2023-05-19Form 4s on file end Jun 23144 ↗
2026-03-31JOHN M EVANS, CEO$569,085
25,000 shplan 2025-05-16144 ↗
Form 4, 2026-04-06: sold 30,078 at $24.58These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting... Form 4 ↗
2026-03-30JOHN M EVANS, CEO$559,230
25,000 shplan 2025-05-16144 ↗
Form 4, 2026-04-01: sold 50,000 at $22.57These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Form 4 ↗
2026-02-24GIUSEPPE CIARAMELLA, President$1,120,042
35,000 shplan 2025-09-30144 ↗
Form 4, 2026-02-26: sold 35,000 at $32.00The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025. Form 4 ↗
2026-01-30JOHN M EVANS, CEO$708,948
25,000 shplan 2025-05-16no Form 4 on file144 ↗
2026-01-29JOHN M EVANS, CEO$734,583
25,000 shplan 2025-05-16144 ↗
Form 4, 2026-02-02: sold 50,000 at $28.87These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Form 4 ↗
2026-01-22CHRISTINE BELLON, Chief Legal Officer$46,614
1,371 shplan 2025-09-16144 ↗
Form 4, 2026-01-26: sold 1,371 at $34.00The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2025. Form 4 ↗
2026-01-15CHRISTINE BELLON, Chief Legal Officer$644,831
18,629 shplan 2025-09-16144 ↗
Form 4, 2026-01-20: sold 18,629 at $34.62The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2025. Form 4 ↗